Munich Information Center for Protein Sequences

Quantum-Si Honored as Proteomics Company of the Year by the BioTech Breakthrough Awards

Retrieved on: 
Wednesday, November 8, 2023
Semiconductor, Health, Technology, General Health, Research, Science, Biotechnology, Platinum, Proteomics, Munich Information Center for Protein Sequences, Protein sequencing, Microscope

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced it has received the “Proteomics Company of the Year” award from the BioTech Breakthrough Awards as part of the program’s 2023 award recipients for its first of a kind protein sequencing instrument.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced it has received the “Proteomics Company of the Year” award from the BioTech Breakthrough Awards as part of the program’s 2023 award recipients for its first of a kind protein sequencing instrument.
  • “Since the groundbreaking introduction of Platinum™, Quantum-Si has swiftly emerged as an industry trailblazer, galvanizing the scientific community with a pioneering focus on proteomics,” said Quantum-Si Chief Executive Officer Jeff Hawkins.
  • This year, the inclusion of a new awards category in proteomics along with three subcategories, signals the immense progress the proteomics industry has made in 2023.
  • Winners in the various categories are featured online at the Biotech Breakthrough Awards website.

Quantum-Si Presents its Vision to Transform Genomics and Proteomics Research at ASHG 2023

Retrieved on: 
Tuesday, October 31, 2023
Research, Technology, Semiconductor, Genetics, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, ASHG, Genomics, Proteomics, Journal of Proteome Research, Booth, Dicarboxylic acid, Phenotype, Protein, Society, Mass spectrometry, American Society of Human Genetics, Drug discovery, Protein sequencing, Human genetics, Platinum, Munich Information Center for Protein Sequences, Microscope

"Platinum, stands as a groundbreaking advancement in next-generation protein sequencing™ moving the field beyond the limitations posed by mass spectrometry and immunoassays.

Key Points: 
  • "Platinum, stands as a groundbreaking advancement in next-generation protein sequencing™ moving the field beyond the limitations posed by mass spectrometry and immunoassays.
  • This robust tool is a solution, enabling precise, single-molecule resolution," remarked Quantum-Si Chief Executive Officer Jeff Hawkins.
  • Additionally, on Thursday, November 2, at 4:30 p.m., Quantum-Si scientists will present: Unleashing Next-generation Protein Sequencing™ with Platinum™: How it will Transform Genomics and Proteomics Research .
  • Its elegant design and simple workflow enable broad-scale access to proteomic data, for every scientist, everywhere, making it a groundbreaking platform for the future of proteomics research.

Quantum-Si to Present at The Festival of Genomics & Biodata 2023 in Boston, Massachusetts

Retrieved on: 
Tuesday, October 3, 2023
Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, DNA, Munich Information Center for Protein Sequences, Senior, New product development, Eye, Protein sequencing, Proteome, Research, Dicarboxylic acid, Proteomics, Protein, Festival, Drug discovery, Vietnam National Convention Center, Biology, Convention center, Platinum, Microscope, Genomics

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the Company and Senior Vice President of Product Development John Vieceli will be presenting at the 2023 Festival of Genomics & Biodata, and first-ever proteomics focused track.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the Company and Senior Vice President of Product Development John Vieceli will be presenting at the 2023 Festival of Genomics & Biodata, and first-ever proteomics focused track.
  • Additionally, Quantum-Si will also be presenting a poster throughout the duration of the conference.
  • The Festival of Genomics & Biodata will take place October 4-5, 2023 at the Convention Center in Boston, Massachusetts.
  • “This year’s Festival of Genomics in Boston includes an eye toward the future of biological research and innovation.

Quantum-Si Appoints Biotech Executive and Entrepreneur, Amir Jafri, to its Board of Directors

Retrieved on: 
Thursday, September 21, 2023
Health, General Health, Munich Information Center for Protein Sequences, Houston Christian University, Cancer, Protein sequencing, Multimedia, Proteomics, Organization, Cardinal Health, Cell Chemical Biology, Biology, ManpowerGroup, Management, Science, History, Chemistry, West Health

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Amir Jafri, President and CEO of Immunicom, Inc., to its Board of Directors.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Amir Jafri, President and CEO of Immunicom, Inc., to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20230921747791/en/
    “Amir’s leadership track record speaks for itself,” said Jeff Hawkins, CEO of Quantum-Si.
  • Previously, Mr. Jafri held executive leadership positions at West Health, Cardinal Health and the Manpower Group.
  • Mr. Jafri is an inventor on over 40 patents covering products and technologies across a range of industries and applications.

Quantum-Si Appoints Life Sciences and Diagnostics Industry Leader Jack Kenny to its Board of Directors

Retrieved on: 
Monday, May 22, 2023
Science, Other Science, Biotechnology, Research, General Health, Health, Technology, Semiconductor, Siemens Healthineers, Bachelor of Science in Human Biology, Quest Diagnostics, Munich Information Center for Protein Sequences, University, Kettering University, Leica Microsystems, Protein sequencing, Multimedia, BD (company), Proteomics, Motivation, Management

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Jack Kenny, CEO of Meridian Bioscience, Inc., to its Board of Directors.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointment of Jack Kenny, CEO of Meridian Bioscience, Inc., to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20230522005246/en/
    “Jack brings a wealth of experience in commercial and operational leadership.
  • He has a proven track record of driving growth at Meridian Bioscience as CEO and also serves on its board of directors.
  • Throughout his career, Mr. Kenny has held additional leadership positions of increasing responsibility for companies including Leica Microsystems, Quest Diagnostics and Bayer Diagnostics.

Quantum-Si Joins Human Proteome Organization (HUPO) Industrial Advisory Board

Retrieved on: 
Thursday, December 8, 2022
Biotechnology, Technology, Other Health, Health, Pharmaceutical, Semiconductor, Health Technology, Research, Genetics, Science, Hardware, Initiative, Conference, Human Proteome Organization, Drug discovery, Partnership, Disease, Protein sequencing, HPP, DNA, Proteomics, Research, Human proteome project, Biology, Proteomics Standards Initiative, COVID-19, Growth, IAB, Munich Information Center for Protein Sequences, Multilateralism, PSI, Risk, Health, Marketing, Congress, Humanitarian use licenses, HUPO, Pharmaceutical industry

Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), The Protein Sequencing Company, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB), an international scientific organization focused on fostering collaboration and promoting new technologies in the proteomics sphere.

Key Points: 
  • Quantum-Si Incorporated (Nasdaq: QSI) (Quantum-Si, QSI or the Company), The Protein Sequencing Company, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB), an international scientific organization focused on fostering collaboration and promoting new technologies in the proteomics sphere.
  • HUPO supports a variety of international initiatives designed to illuminate the molecular features that dictate human health or disease, including the Human Proteome Project (HPP) , Initiative for Model Organism Proteomics (iMOP) , and Proteomic Standards Initiative (PSI) .
  • Quantum-Si is participating in the 21st HUPO World Congress, which is currently taking place in Cancun, Mexico, on December 4-8, 2022.
  • Founded in 2001, the Human Proteome Organization (HUPO) is a 501(c)(3) tax exempt non-profit organization registered in the state of New Mexico.